Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioid REMS: New CME 'Blueprint' To Include Immediate-Release Drugs

Executive Summary

US FDA is moving forward on two fronts to update and improve the Risk Evaluation & Mitigation Strategy to help limit misuse and abuse of opioid pain medications: the agency has a plan to incorporate IR sponsors into the existing REMS, and also a new 'blueprint' for the prescriber education that focuses on pain management.

You may also be interested in...



Opioid REMS Revisions Reflect Some, Not All, Stakeholder Concerns

US FDA's education blueprint now asks sponsors to extend REMS to health providers beyond prescriber, but pain classifications remain unchanged.

Opioid Litigation: Court Asks US FDA To Attend Education Session

Judge overseeing multidistrict litigation convenes meeting with senior pharma executives, government plaintiffs and others to learn about supply-chain dynamics and other issues to resolve more than 200 suits.

FDA Expands Opioid Abuse Research, Outreach

US agency signs contracts for more real-world data on abuse; officials also meet with AMA representatives to discuss opioid prescriber education.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel